Health-related Quality of Life in Relapsing Remitting Multiple Sclerosis Patients During Treatment With Glatiramer Acetate: A Prospective, Observational, International, Multi-Centre Study

Health Qual Life Outcomes. 2010 Nov 15;8:133. doi: 10.1186/1477-7525-8-133.

Abstract

Background: Glatiramer acetate (GA) and interferon-beta (INFb) are first-line disease modifying drugs for relapsing remitting multiple sclerosis (RRMS). Treatment with INFb is associated with a significant increase in health-related quality of life (HR-QoL) in the first 12 months. It is not known whether HR-QoL increases during treatment with GA.

Methods: 197 RRMS patients, 106 without and 91 with prior immunomodulation/immunosuppression, were studied for HR-QoL (Leeds Multiple Sclerosis-QoL [LMS-QoL] scale, score range 0 - 32), fatigue (Fatigue Impact Scale [FIS]) and depressed mood (Beck Depression Inventory-Short Form [BDI-SF]) at baseline and 6 and 12 months after start of GA treatment.

Results: At 6 and 12 months mean LMS-QoL scores were significantly increased in the treatment-naive patient group (p < 0.001), not in the pre-treated group. At month 12 43% of treatment-naïve patients had improved HR-QoL (increase LMS-QoL score 3 or more points) (p < 0.001). Likewise, mean FIS scores were decreased at months 6 and 12 in the treatment-naïve group (p < 0.01), not in the pre-treated group. In both groups mean BDI-SF scores did not change. No demographic or clinical baseline factor was predictive of HR-QoL increase. HR-QoL changes were zero to negative for patients who had discontinued GA before month 12 (28.4% of patients).

Conclusions: In RRMS patients without prior immunomodulation/immunosuppression treatment with GA was associated with an increase in HR-QoL in the first 6 months, that was sustained at 12 months. In 4 out of 10 patients HR-QoL improved. Increase in HR-QoL was associated with decrease in fatigue.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Dose-Response Relationship, Drug
  • Female
  • Glatiramer Acetate
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Interferon-beta / therapeutic use*
  • Male
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Peptides / therapeutic use*
  • Prospective Studies
  • Psychometrics
  • Qualitative Research
  • Quality of Life / psychology*
  • Surveys and Questionnaires

Substances

  • Immunosuppressive Agents
  • Peptides
  • Glatiramer Acetate
  • Interferon-beta